Chronic hepatitis Delta virus (HDV) infection represents the most severe form of viral hepatitis, characterized by accelerated progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. For decades, Pegylated Interferon (PegIFNα) has been the only therapeutic option, with limited efficacy and poor tolerability. The approval of the HBV/HDV entry inhibitor Bulevirtide marked a turning point, by providing the first anti-HDV specific antiviral drug. This position paper, developed jointly by the Italian Association for the Study of the Liver (AISF) and the Italian Society of Infectious and Tropical Diseases (SIMIT), updates prior national guidance by providing practical recommendations for diagnosis, staging, and treatment of chronic HDV infection.

Degasperi, E., Pisaturo, M., Aghemo, A., Andreoni, M., Brunetto, M., Calvaruso, V., et al. (2026). AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update. DIGESTIVE AND LIVER DISEASE, 58(3), 297-307 [10.1016/j.dld.2025.12.017].

AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update

Puoti M.;
2026

Abstract

Chronic hepatitis Delta virus (HDV) infection represents the most severe form of viral hepatitis, characterized by accelerated progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. For decades, Pegylated Interferon (PegIFNα) has been the only therapeutic option, with limited efficacy and poor tolerability. The approval of the HBV/HDV entry inhibitor Bulevirtide marked a turning point, by providing the first anti-HDV specific antiviral drug. This position paper, developed jointly by the Italian Association for the Study of the Liver (AISF) and the Italian Society of Infectious and Tropical Diseases (SIMIT), updates prior national guidance by providing practical recommendations for diagnosis, staging, and treatment of chronic HDV infection.
Articolo in rivista - Review Essay
Bulevirtide; Chronic hepatitis delta; Cirrhosis; HDV RNA; Hepatitis D virus; PegIFN; Virological response;
English
28-gen-2026
2026
58
3
297
307
open
Degasperi, E., Pisaturo, M., Aghemo, A., Andreoni, M., Brunetto, M., Calvaruso, V., et al. (2026). AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update. DIGESTIVE AND LIVER DISEASE, 58(3), 297-307 [10.1016/j.dld.2025.12.017].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1590865825012575-main.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/628981
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
Social impact